OBJECTIVES: One of the main treatment goals in rheumatoid arthritis (RA), for which there is no curative treatment so far, is to improve Health Related Quality of Life (HRQoL) and patient satisfaction with treatment. The Willingness to pay (WTP) method can be used as a tool to assess patient preferences and the perceived value of non-marketed goods intangible goods. Although the efficacy of adalimumab and infliximab in the treatment of RA might be the same, the differences in administration route and dosage might impact patient preferences and perceived value of the drugs. METHODS: We carried out a WTP study in RA patients, currently treated with infliximab, assessing patient’s WTP in the open-ended with follow-up format. We presented a new treatment, adalimumab, with the same efficacy as infliximab but with some differential attributes, mainly the possibility to self-administer the subcutaneous injection, administration at home, minor time for administration, ergonomic design for being self-administrating, and finally presentation just for being used. RESULTS: In total, 91 patients were included in the study, of which 76 (83.5%) were WTP for the new treatment. The mean WTP was 103.4€ per month, which represents the 9% of the patient’s monthly rent. Patients with poorest health states presented the lowest monthly WTP as compared with those with the best-perceived health state (83€ vs. 121€). No differences were found in the WTP according to other sociodemographic or clinical variables. CONCLUSIONS: The new treatment is preferred by most of AR patients, mainly due to the reduced administration time, which drives a willingness to pay of 9% of the monthly rent of the patient on average.